Carl Firth

Partner at Panacea Ventures

Speaker

Dr Carl Firth is Partner at Panacea Venture, a global investment fund focused on healthcare. Previously, Carl was CEO and founder of ASLAN Pharmaceuticals, a NASDAQ-listed clinical stage biotech, which he took public in 2018 and raised over $300M from leading global investors including BVF, Orbimed and RTW.

Prior to founding ASLAN, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions. Before joining the banking industry, he worked for AstraZeneca across various commercial and R&D roles.

Carl currently serves as a board member and advisor to several biotech companies. Carl is an Adjunct Professor at Duke-NUS Medical School and has a PhD in Computational Biology and BA in Molecular Biology from Cambridge University (Trinity College), and an Executive MBA from London Business School.